{
  "id": 9139481,
  "title": "Why the Pentagon Keeps Funding This Small Cap (Nasdaq: MDWD)",
  "url": "https://urgent.news/2026/09/22/why-the-pentagon-keeps-funding-this-small-cap-nasdaq-mdwd",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-22T12:31:12.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/why-the-pentagon-keeps-funding-this-small-cap-nasdaq-mdwd-4910775"
  },
  "original_language": "en",
  "account": "The Pentagon has been funding a program for over a decade that enables MediWound, a small-cap biotech company (Nasdaq: MDWD), to develop a topical gel called NexoBrid. This gel dissolves dead tissue from severe burns in four hours without the need for a scalpel or an operating room. The Department of War has added to the program multiple times, bringing the total budget to $21.8 million. The latest award is $3.3 million, making the program's budget $3.3 million. The program is not just about MediWound's financial success; it also addresses a critical problem in mass casualty events where operating rooms and surgical teams are overwhelmed, leading to increased risk of infection. The gel, an FDA-approved biologic called NexoBrid, is already approved in 45 countries and is stored in the U.S. Strategic National Stockpile. The funding covers a critical development step between an approved hospital product and a field-ready one, making it deployable in austere settings. NexoBrid has already seen commercial success, with Vericel reporting record revenue for the second quarter of 2026 and MediWound advancing EscharEx in a global Phase III VALUE trial. The Pentagon's funding across multiple administrations and agencies highlights its consistent confidence in MediWound's technology.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}